Photo from wikipedia
The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56 + NK cell numbers, NKG2D… Click to show full abstract
The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56 + NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR) + cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR + CD56 dim or cytokine-responsive CD56 bright NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans.
Journal Title: NPJ Vaccines
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!